Literature DB >> 10976525

Attempts to obtain more efficient GAC-cleaving hammerhead ribozymes by in vitro selection.

A R Kore1, C Carola, F Eckstein.   

Abstract

An in vitro selection was carried out to identify hammerhead ribozymes cleaving 3' to GAC triplets more efficiently than the wild type ribozyme. A double-stranded DNA containing the sequence for the hammerhead ribozyme with 10 randomizations in the catalytic core, designed for in cis cleavage, was transcribed and the cleavage product amplified by reverse transcription and PCR. After seven selection cycles, the DNA was cloned and 50 colonies sequenced. One sequence, appearing six times, was active for in cis cleavage of GAC. It was identical to the consensus sequence except for a mutation at position 7. Another cleaved GUC and two more, cleaved GUA. The cleavage rates of these ribozymes for in trans cleavage were slower than the rate of the consensus ribozyme. Interestingly, the consensus sequence was not found in the selection. This strongly suggests that the consensus hammerhead ribozyme has evolved to an optimal sequence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10976525     DOI: 10.1016/s0968-0896(00)00103-6

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

Review 1.  The ubiquitous hammerhead ribozyme.

Authors:  Christian Hammann; Andrej Luptak; Jonathan Perreault; Marcos de la Peña
Journal:  RNA       Date:  2012-03-27       Impact factor: 4.942

2.  Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1.

Authors:  Hoshang J Unwalla; Haitang Li; Shi-Yang Li; Danny Abad; John J Rossi
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

3.  G17-modified hammerhead ribozymes are active in vitro and in vivo.

Authors:  Anne Kalweit; Christian Hammann
Journal:  RNA       Date:  2013-10-21       Impact factor: 4.942

4.  Hitting bacteria at the heart of the central dogma: sequence-specific inhibition.

Authors:  Louise Carøe Vohlander Rasmussen; Hans Uffe Sperling-Petersen; Kim Kusk Mortensen
Journal:  Microb Cell Fact       Date:  2007-08-10       Impact factor: 5.328

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.